

MATERIAL ADICIONAL

Nota explicativa

Se presenta la bibliografía completa de los 17 estudios incluidos en el análisis cuantitativo del metanálisis. Algunas de estas referencias también se citan en la bibliografía principal del manuscrito por su relevancia metodológica o clínica.

BIBLIOGRAFÍA DEL MATERIAL ADICIONAL

1. Montalescot G, Van't Hof AW, Lapostolle F, et al. Prehospital ticagrelor in ST-segment elevation myocardial infarction. *N Engl J Med*. 2014;37:1016-1027.
2. Zeymer U, Arntz HR, Mark B, et al. Efficacy and safety of a high loading dose of clopidogrel administered prehospitally to improve primary percutaneous coronary intervention in acute myocardial infarction: the randomized CIPAMI trial. *Clin Res Cardiol*. 2012;101:305-312.
3. Pepe M, Cafaro A, Paradies V, et al. Time-dependent benefits of pre-treatment with new oral P2Y12-inhibitors in patients addressed to primary PCI for acute ST-elevation myocardial infarction. *Catheter Cardiovasc Interv*. 2019;93:592-601.
4. Gallo F, Cutolo A, Antonucci A, et al. Clinical impact of P2Y12 pretreatment in ST-segment elevation myocardial infarction: insights from the SEMPRES (St-Elevation Mestres Pretreatment Registry) Study. *Am J Cardiol*. 2025;243:1-7.
5. Yudi MB, Farouque O, Andrianopoulos N, et al. Pretreatment with dual antiplatelet therapy in patients with ST-elevation myocardial infarction. *Catheter Cardiovasc Interv*. 2018;92:E98-E105.
6. Ducci K, Grotti S, Falsini G, et al. Comparison of pre-hospital 600 mg or 900 mg vs. per-interventional 300 mg clopidogrel in patients with ST-elevation myocardial infarction undergoing primary coronary angioplasty. The Load&Go randomized trial. *Int J Cardiol*. 2013;168:4814-4816.

7. Lupi A, Schaffer A, Lazzeri M, et al. Pre-hospital ticagrelor in patients with ST-segment elevation myocardial infarction with long transport time to primary PCI facility. *Cardiovasc Revasc Med*. 2016;17:528-534.
8. Lev EI, Kornowski R, Vaknin-Assa H, et al. Effect of clopidogrel pretreatment on angiographic and clinical outcomes in patients undergoing primary percutaneous coronary intervention for ST-elevation acute myocardial infarction. *Am J Cardiol*. 2008;101:435-439.
9. Redfors B, Dworeck C, Haraldsson I, et al. Pretreatment with P2Y12 receptor antagonists in ST-elevation myocardial infarction: a report from the Swedish Coronary Angiography and Angioplasty Registry. *Eur Heart J*. 2019;40:1202-1210.
10. Danchin N, Puymirat E, Cayla G, et al. One-Year Survival After ST-segment elevation myocardial infarction in relation with prehospital administration of dual antiplatelet therapy: The FAST-MI Program. *Circ Cardiovasc Interv*. 2018;11:e007241.
11. Moura Guedes JP, Marques N, Azevedo P, et al. A loading dose of a P2Y12 inhibitor before entering the catheterization lab in patients with ST-segment elevation acute myocardial infarction – Is this really the best strategy? *Rev Port Cardiol*. 2020;39:553-561.
12. De Waha S, Eitel I, Desch S, et al. Association of upstream clopidogrel administration and myocardial reperfusion assessed by cardiac magnetic resonance imaging in patients with ST-elevation myocardial infarction. *Eur Heart J Acute Cardiovasc Care*. 2014;3:110-117.
13. Fefer P, Hod H, Hammerman H, et al. Usefulness of pretreatment with high-dose clopidogrel in patients undergoing primary angioplasty for ST-elevation myocardial infarction. *Am J Cardiol*. 2009;104:514-518.
14. Rohla M, Ye SX, Shibutani H, et al. Pretreatment with P2Y12 inhibitors in ST-segment elevation myocardial infarction. *JACC Cardiovasc Interv*. 2024;17:17-28.
15. Ikegami Y, Kohsaka S, Miyata H, et al. Outcomes of percutaneous coronary intervention performed with or without preprocedural dual antiplatelet therapy. *Circ J*. 2015;79:2598-2607.

16. Almendro-Delia M, Hernández-Meneses B, Padilla-Rodríguez G, et al. Timing of P2Y12 inhibitor administration in patients with STEMI undergoing primary PCI. *J Am Coll Cardiol.* 2024;83:2629-2639.
17. Dorler J, Edlinger M, Alber HF, et al. Clopidogrel pre-treatment is associated with reduced in-hospital mortality in primary percutaneous coronary intervention for acute ST-elevation myocardial infarction. *Eur Heart J.* 2011;32:2954-2961.